Galmed Pharmaceuticals Ltd. (GLMD)
Pre-Market:
Galmed Pharmaceuticals Ltd.
16 Tiomkin Street
Tel Aviv 6578317
Israel
972 3 693 8448
https://www.galmedpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 3
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Allen Baharaff | Co-Founder, President, CEO & Chairman | 972.16k | N/A | 1965 |
| Mr. Doron Cohen | Chief Financial Officer | 245.98k | N/A | 1967 |
| Mr. Guy Nehemya | COO & Data Protection Officer | 287.04k | N/A | 1985 |
| Mr. Yohai Stenzler CPA | Chief Accounting Officer | 290.57k | N/A | 1983 |
| Dr. Liat Hayardeny | Chief Scientific Officer | 47.93k | N/A | 1967 |
| Ms. Yael Hollander | Vice President of Legal Affairs & Strategy | 134.21k | N/A | 1983 |
| Ms. Shani Ganon | Human Resources Manager | N/A | N/A | N/A |
| Dr. Tali Gorfine | Medical Consultant | 202.76k | N/A | 1970 |
Description
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Corporate Governance
Galmed Pharmaceuticals Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
